Differential activation of CC chemokine receptors by AOP-RANTES.
RANTES (regulated on activation normal T cell expressed) has been found at elevated levels in biological fluids from patients with a wide range of allergic and autoimmune diseases and is able to attract several subtypes of leukocytes including eosinophils and monocytes into inflamed tissue. Amino-terminal modifications of RANTES produce receptor antagonists which are candidates for blocking this cellular recruitment. Met-RANTES has been shown to modulate inflammation in vivo, while AOP-RANTES is a potent inhibitor of R5 human immunodeficiency virus type 1 (HIV-1) strains and has been shown to down-modulate CCR5 and prevent recycling of the receptor. We have studied the effect of AOP-RANTES in eosinophil activation and have found that it is able to efficiently elicit eosinophil effector functions through CCR3, as measured by the release of reactive oxygen species and calcium mobilization, whereas Met-RANTES is inactive in these assays. AOP-RANTES is found to inhibit CCR3-mediated HIV-1 infection with moderate potency, in contrast to its potent inhibition of CCR5-mediated HIV-1 infection. Furthermore, we have investigated the abilities of these modified proteins to down-modulate CCR1 and CCR3 from the surface of monocytes and eosinophils. We show here that AOP-RANTES is much less effective than RANTES in down-modulation of CCR1. Surprisingly, recycling of CCR1 was minimal after incubation with RANTES while there was complete recycling with AOP-RANTES. In the case of CCR3, no significant difference was found between RANTES and AOP-RANTES in down-modulation and recycling. It therefore appears that trafficking of RANTES receptors follows different patterns, which opens up potential new targets for therapeutic intervention.
Elsner
J
J
Department of Dermatology and Allergology, Hannover Medical University, 30449 Hannover, Germany.
Mack
M
M
Brühl
H
H
Dulkys
Y
Y
Kimmig
D
D
Simmons
G
G
Clapham
P R
PR
Schlöndorff
D
D
Kapp
A
A
Wells
T N
TN
Proudfoot
A E
AE
D019380:Anti-HIV Agents / Q000494:pharmacology; D020013:Calcium Signaling; D054413:Chemokine CCL11; D018946:Chemokine CCL5 / Q000031:analogs & derivatives* / Q000494:pharmacology; D019742:Chemokines, CC / Q000378:metabolism*; D016207:Cytokines / Q000494:pharmacology; D015536:Down-Regulation; D004804:Eosinophils / Q000276:immunology*; D015497:HIV-1 / Q000254:growth & development; D006801:Humans; D017382:Reactive Oxygen Species / Q000378:metabolism; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019713:Receptors, CCR5 / Q000187:drug effects; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000821:virology
D019380:Anti-HIV Agents; C515456:CCL11 protein, human; C515300:CCR1 protein, human; C515350:CCR3 protein, human; D054413:Chemokine CCL11; D018946:Chemokine CCL5; D019742:Chemokines, CC; D016207:Cytokines; C108335:RANTES, Met-; D017382:Reactive Oxygen Species; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; C111989:aminooxypentane-RANTES